High Density Lipoprotein: a Therapeutic Target in Type 2 Diabetes

Overview

Journal Endocrinol Metab (Seoul)

Specialty Endocrinology

Date 2014 Jan 8

PMID 24396675

Citations 14

Authors

Philip J Barter

Affiliations

Soon will be listed here.

Abstract

High density lipoproteins (HDLs) have a number of properties that have the potential to inhibit the development of atherosclerosis and thus reduce the risk of having a cardiovascular event. These protective effects of HDLs may be reduced in patients with type 2 diabetes, a condition in which the concentration of HDL cholesterol is frequently low. In addition to their potential cardioprotective properties, HDLs also increase the uptake of glucose by skeletal muscle and stimulate the synthesis and secretion of insulin from pancreatic β cells and may thus have a beneficial effect on glycemic control. This raises the possibility that a low HDL concentration in type 2 diabetes may contribute to a worsening of diabetic control. Thus, there is a double case for targeting HDLs in patients with type 2 diabetes: to reduce cardiovascular risk and also to improve glycemic control. Approaches to raising HDL levels include lifestyle factors such as weight reduction, increased physical activity and stopping smoking. There is an ongoing search for HDL-raising drugs as agents to use in patients with type 2 diabetes in whom the HDL level remains low despite lifestyle interventions.

Citing Articles

HDL-C criterion of the metabolic syndrome and future diabetes and atherosclerosis in midlife women: The SWAN Study.

Wang Z, Barinas-Mitchell E, Brooks M, Crawford S, Leis A, Derby C Am J Prev Cardiol. 2024; 19:100687.

PMID: 39070021 PMC: 11279330. DOI: 10.1016/j.ajpc.2024.100687.

Association between high-density lipoprotein cholesterol and type 2 diabetes mellitus: dual evidence from NHANES database and Mendelian randomization analysis.

Yan Z, Xu Y, Li K, Liu L Front Endocrinol (Lausanne). 2024; 15:1272314.

PMID: 38455653 PMC: 10917910. DOI: 10.3389/fendo.2024.1272314.

High Vaccenic Acid Content in Beef Fat Attenuates High Fat and High Carbohydrate Western Diet Induced Changes in Lipid Metabolism and Gut Microbiota in Pigs.

Singh V, Fontaine M, Mangat R, Fouhse J, Diane A, Willing B Microorganisms. 2021; 9(12).

PMID: 34946118 PMC: 8707829. DOI: 10.3390/microorganisms9122517.

Inverse Association between High-Density Lipoprotein Cholesterol and Adverse Outcomes among Acute Ischemic Stroke Patients with Diabetes Mellitus.

Hu G, Pan Y, Wang M, Meng X, Jiang Y, Li Z Biomedicines. 2021; 9(12).

PMID: 34944763 PMC: 8698640. DOI: 10.3390/biomedicines9121947.

Impaired Glucose Metabolism in People with Extremely Elevated High-Density Lipoprotein Cholesterol and Low Alcohol Consumption: Results of the Kanagawa Investigation of Total Checkup Data from the National Database-3 (KITCHEN-3).

Nakajima K, Higuchi R J Clin Med. 2019; 8(11).

PMID: 31683881 PMC: 6912278. DOI: 10.3390/jcm8111825.

References

Barter P, Rye K . Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res. 2012; 53(9):1755-66. PMC: 3413218. DOI: 10.1194/jlr.R024075. View

Ginsberg H, Elam M, Lovato L, Crouse 3rd J, Leiter L, Linz P . Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1563-74. PMC: 2879499. DOI: 10.1056/NEJMoa1001282. View

Boden W, Probstfield J, Anderson T, Chaitman B, Desvignes-Nickens P, Koprowicz K . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24):2255-67. DOI: 10.1056/NEJMoa1107579. View

Maeda K, Noguchi Y, Fukui T . The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med. 2003; 37(4):283-90. DOI: 10.1016/s0091-7435(03)00110-5. View

Nicholls S, Cutri B, Worthley S, Kee P, Rye K, Bao S . Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 2005; 25(11):2416-21. DOI: 10.1161/01.ATV.0000184760.95957.d6. View

FRICK M, ELO O, Haapa K, Heinonen O, Heinsalmi P, Helo P . Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317(20):1237-45. DOI: 10.1056/NEJM198711123172001. View

Kearney P, Blackwell L, Collins R, Keech A, Simes J, Peto R . Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371(9607):117-25. DOI: 10.1016/S0140-6736(08)60104-X. View

Barter P, Rye K, Tardif J, Waters D, Boekholdt S, Breazna A . Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011; 124(5):555-62. DOI: 10.1161/CIRCULATIONAHA.111.018259. View

Duggal J, Singh M, Attri N, Singh P, Ahmed N, Pahwa S . Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2010; 15(2):158-66. DOI: 10.1177/1074248410361337. View

10.

Nissen S, Tardif J, Nicholls S, Revkin J, Shear C, Duggan W . Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007; 356(13):1304-16. DOI: 10.1056/NEJMoa070635. View

11.

Hayashino Y, Jackson J, Fukumori N, Nakamura F, Fukuhara S . Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2012; 98(3):349-60. DOI: 10.1016/j.diabres.2012.10.004. View

12.

Schwartz G, Olsson A, Abt M, Ballantyne C, Barter P, Brumm J . Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367(22):2089-99. DOI: 10.1056/NEJMoa1206797. View

13.

Villines T, Stanek E, Devine P, Turco M, Miller M, Weissman N . The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment.... J Am Coll Cardiol. 2010; 55(24):2721-6. DOI: 10.1016/j.jacc.2010.03.017. View

14.

Badimon J, Badimon L, Fuster V . Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990; 85(4):1234-41. PMC: 296557. DOI: 10.1172/JCI114558. View

15.

Bots M, Visseren F, Evans G, Riley W, Revkin J, Tegeler C . Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007; 370(9582):153-160. DOI: 10.1016/S0140-6736(07)61088-5. View

16.

Nicholls S, Gordon A, Johansson J, Wolski K, Ballantyne C, Kastelein J . Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011; 57(9):1111-9. DOI: 10.1016/j.jacc.2010.11.015. View

17.

Barter P, Caulfield M, Eriksson M, Grundy S, Kastelein J, Komajda M . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-22. DOI: 10.1056/NEJMoa0706628. View

18.

Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S . RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010; 55(23):2580-9. DOI: 10.1016/j.jacc.2010.02.035. View

19.

Hoang A, Murphy A, Coughlan M, Thomas M, Forbes J, OBrien R . Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia. 2007; 50(8):1770-9. DOI: 10.1007/s00125-007-0718-9. View

20.

Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih D . Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011; 121(7):2693-708. PMC: 3223817. DOI: 10.1172/JCI42946. View